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Background. Fifty percent of lung adenocarcinomas harbor somatic mutations in six genes that encode proteins in the EGFR
signaling pathway, i.e., EGFR, HER2/ERBB2, HER4/ERBB4, PIK3CA, BRAF, and KRAS. We performed mutational profiling of a large
cohort of lung adenocarcinomas to uncover other potential somatic mutations in genes of this signaling pathway that could
contribute to lung tumorigenesis. Methodology/Principal Findings. We analyzed genomic DNA from a total of 261 resected,
clinically annotated non-small cell lung cancer (NSCLC) specimens. The coding sequences of 39 genes were screened for
somatic mutations via high-throughput dideoxynucleotide sequencing of PCR-amplified gene products. Mutations were
considered to be somatic only if they were found in an independent tumor-derived PCR product but not in matched normal
tissue. Sequencing of 9MB of tumor sequence identified 239 putative genetic variants. We further examined 22 variants found
in RAS family genes and 135 variants localized to exons encoding the kinase domain of respective proteins. We identified
a total of 37 non-synonymous somatic mutations; 36 were found collectively in EGFR, KRAS, BRAF, and PIK3CA. One somatic
mutation was a previously unreported mutation in the kinase domain (exon 16) of FGFR4 (Glu681Lys), identified in 1 of 158
tumors. The FGFR4 mutation is analogous to a reported tumor-specific somatic mutation in ERBB2 and is located in the same
exon as a previously reported kinase domain mutation in FGFR4 (Pro712Thr) in a lung adenocarcinoma cell line. Conclusions/
Significance. This study is one of the first comprehensive mutational analyses of major genes in a specific signaling pathway
in a sizeable cohort of lung adenocarcinomas. Our results suggest the majority of gain-of-function mutations within kinase
genes in the EGFR signaling pathway have already been identified. Our findings also implicate FGFR4 in the pathogenesis of
a subset of lung adenocarcinomas.
Citation: Marks JL, McLellan MD, Zakowski MF, Lash AE, Kasai Y, et al (2007) Mutational Analysis of EGFR and Related Signaling Pathway Genes in
Lung Adenocarcinomas Identifies a Novel Somatic Kinase Domain Mutation in FGFR4. PLoS ONE 2(5): e426. doi:10.1371/journal.pone.0000426
INTRODUCTION
Lung cancer is the leading cause of cancer-related death in the
United States and worldwide [1]. Despite recent advances in the
treatment of lung cancer, the overall 5-year survival in the United
States remains only 15%, highlighting the need for novel
treatment strategies.
Lung cancers are currently classified into two major groups
depending on histology: small cell lung cancer and non-small cell
lung cancer (NSCLC). The latter is comprised of three different
subtypes: adenocarcinoma, squamous cell carcinoma, and large
cell carcinoma. The incidence of the adenocarcinoma subtype has
been rising and now accounts for .50% of all cases of lung cancer
[2]. Standard treatment for metastatic lung cancer involves
empiric cytotoxic chemotherapy.
In order to develop specific therapies based upon the genetic
makeup of individual NSCLC tumors, we (the Lung Cancer
Oncogenome Group at Memorial Sloan-Kettering Cancer Center
(MSKCC)) and others have sought to define clinically relevant
molecular subsets of lung cancer. For example, we and others have
shown that tumors highly sensitive to epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (i.e. gefitinib or
erlotinib) often contain dominant mutations in exons which
encode a portion of the tyrosine kinase (TK) domain of EGFR [3–
5]. Conversely, tumors with somatic mutations in KRAS, which
encodes a GTPase downstream of EGFR, are resistant to therapy
with these drugs [6–8]. Furthermore, about half of tumors with
acquired resistance to these drugs display a second-site mutation in
EGFR (Thr790Met) [9,10]. Taken together, these data suggest that
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be used to predict sensitivity and resistance to gefitinib and
erlotinib. Clinicians in the future may be able to prescribe
additional targeted therapies for patients with NSCLC based upon
specific molecular characteristics.
At least six EGFR signaling pathway genes have been found to be
mutated in NSCLC. While EGFR and KRAS mutations are detected
in ,10% and 20% of NSCLCs, respectively, somatic mutations
have also been identified in HER2/ERBB2 (,2%; exons 19 and 20)
[11,12] and HER4 (,2%, exons 20, 23) [13], the lipid kinase
PIK3CA (,4%; exon 9) [14], and the serine/threonine kinase BRAF
(,2%; exons 11 and 15) [15–17]. Most of these alterations have
been found to be gain-of-function mutations. Except for PIK3CA
mutations [18,19], mutations inone of the other five genes are rarely
found to be accompanied by a mutation in any of the remaining
four, suggesting that they may have functionally equivalent roles in
lung tumorigenesis [20]. All of these mutations are predominantly
found in tumors with adenocarcinoma histology.
To uncover other potential gain-of-function somatic mutations
that could have biological and clinical relevance in lung cancer, we
performed mutational profiling of a large cohort of lung tumors,
mostly adenocarcinomas. Because multiple genes that encode
proteins in the EGFR signaling pathway have been found to be
mutated in lung adenocarcinomas, we specifically sought to identify
potential gain-of-function mutations ingene families inthis pathway,
i.e. in ERBB1-4, PIK3CA, AKT1-3, FRAP1, RPS6K1-2, RAS (K-, N-,
and H-), RAF (A-, B-, C-), MAP2K1-2,a n dMAPK-1-3. We extended
our studies to include other members of the MAP2K and MAPK
gene families. We also examined FGFR1-4, because overexpression
of FGF ligands in mouse lung epithelia leads to alveolar type II cell
hyperplasiaand adenomas [21–23]. All 39 genes have been reported
to be expressed in mammalian lung tissues.
METHODS
Tissue procurement
Resected tumor and matched normal adjacent lung specimens
were obtained with patients’ consent from the Memorial Sloan-
Kettering Cancer Center (MSKCC) lung cancer tissue bank via
a protocol approved by the Institutional Review Board (protocol
#92-055). At the time of resection, samples were snap-frozen in
the operating room in liquid nitrogen and then stored at minus
80uC until the time of use. Specimens were reviewed by a single
pathologist (MFZ) for $70% tumor content and for histological
verification. Clinical information was obtained from existing
institutional databases. Some data regarding the mutation status
of EGFR was previously reported [5].
Mutational profiling
Tumors selected for analyses were enriched for lung adenocarcino-
masbutwereotherwiserandomlyselected,baseduponavailabilityof
tissue. Squamous cell carcinomas were included to fill-in otherwise
empty plate wells. No large cell carcinomas were studied.
DNA was extracted from tumors using a kit (DNeasy, Qiagen)
or standard phenol extraction. Whole genome amplification
(WGA) was performed by Qiagen. High-throughput (96-well
plate) bidirectional dideoxynucleotide sequencing of PCR-ampli-
fied gene products was performed at the Genome Sequencing
Center (Washington University in St. Louis) as per standard
protocol (http://genome.wustl.edu/activity/med_seq/protocols.
cgi). The primer list can be found at: http://genome.wustl.edu/
platforms.cgi?id=7.
PolyPhred [24] and PolyScan [25] software were used to
generate an initial ‘‘automated’’ report of sequence variations.
Tumor sequences were compared against reference sequences
listed in the NCBI (RefSeq) database for each respective gene (see
Supplemental Table S1). After visual inspection of the
individual forward and reverse chromatograms for confirmation
of non-synonymous sequence variations and insertions or deletions
(including duplications), a ‘‘manual review’’ list of potential
nucleotide changes was produced. Synonymous variants and
those with corresponding dbSNP (www.ncbi.nlm.nih.gov/
projects/SNP/) entries were also excluded.
Mutation verification
Putative kinase domain mutations listed in the manual report were
subsequently verified at MSKCC by bidirectional sequence
analysis of a separate individual PCR product. Variants were
deemed somatic if they were found to be absent in matched
normal tissue. Primers were designed to detect each individual
mutation, using each respective reference sequence and Vector
NTI (Supplemental Tables S1 and S2). All PCR reactions
were performed with HotStarTaq Master Mix Kit (Qiagen,
Valencia, California), using standard conditions (95uC615 min;
95uC630 s, 60uC630 s, 72uC660 s, for 36 cycles, then 72uC for
5 minutes, 50 ml reactions). PCR products were purified with
a MultiScreen Resist vacuum manifold and PCR96 Cleanup Plates
(Millipore). Sequencing reactions were performed using Applied
Biosystems Version 3.1 Big Dye Terminator chemistry and
analyzed on an Applied Biosystems 3730 Sequencer.
Development of ‘‘Mutagrator’’ – a mutation
interpretation tool for tyrosine kinases
To support the interpretation of putative kinase domain muta-
tions, we created a prototype mutation interpretation tool for
tyrosine kinases (TKs), called ‘‘Mutagrator’’, located at http://
cbio.mskcc.org/,lash/mutagrator/ (freely available to the re-
search community). Mutagrator is a software program which takes
curated mutation data from the literature and displays it in the
context of a master protein (chosen by the user) and a protein-
registered TK multiple domain alignment. In order to create the
multiple alignment, we first retrieved 108 human TK gene records
from EntrezGene by querying for domain cd00192 [26]. We then
extracted TK domains from all 168 protein isoforms correspond-
ing to these genes from Entrez Protein [27], aligned the domains
using the ClustalW program [28], and added additional feature
information, including ATP binding residues, activation loop,
catalytic loop and substrate binding site boundaries from
Conserved Domain Database (CDD) [29]. All input and output
files are available on the Mutagrator website. Currently, curated
mutation data is ingested from the Catalogue of Somatic
Mutations in Cancer (COSMIC), which was created and is
maintained by the Sanger Institute [30]. Collected data includes
mutation (amino acid change and position), mutation type (point,
insertion, deletion, complex), involved gene, tissue type, cancer
type and published source. The version of the database used in this
study (v20) consisted of about 30,000 individual mutations in
about 1,300 genes, and corresponding to about 3,300 distinct
mutations. From these data, Mutagrator produced interlinked,
static HTML webpages of two types: master protein pages (for
each protein in the TK domain alignment with mutations), and
detailed mutation pages (for each protein residue position).
RESULTS
We screened coding sequences from 39 genes for mutations in
genomic DNA from a total of 261 resected, clinically annotated
non-small cell lung cancer (NSCLC) specimens. 90% of tumors
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Clinical characteristics of examined tumors are listed in Supple-
mental Table S3, and the exonic coverage of genes is listed in
Supplemental Table S1.
Due to logistical reasons, the mutational analysis was performed
in two partially overlapping groups. We first examined genomic
DNAs from 217 tumors for mutations in a set of core genes
previously reported to harbor mutations in NSCLC, i.e. in EGFR,
HER2, HER4, KRAS, PIK3CA, and BRAF (Figure 1). We also
profiled HER3, MAP2K4, and FGFR1-4 (Figure 1). We then
examined 93 WGA-treated DNA tumor samples for mutations in
EGFR pathway genes and a set of exploratory genes (Figure 1).
Ten genes were sequenced in both groups (Figure 1) to maximize
the number of tumors sequenced for the core genes. Eighty
percent of the sequence reads in the WGA-treated specimens had
a Phred quality score of at least 20 (data not shown), suggesting
that most base-calling had an accuracy of 99% [31].
Automatic and manual sequence analyses (see methods)
identified 239 putative non-synonymous sequence variations,
comprised of 174 different types of variants that differed from
published sequences (Figure 2, and Supplemental Table S1).
To focus our efforts, we concentrated on further examining the 22
variants (6 types) found in 3 RAS family genes and the 135
variants (99 types) found within exons encoding kinase domains of
kinases. The 82 non-kinase domain variants (69 distinct types)
have not yet been examined, although none occur at a frequency
higher than 2%.
We confirmed 21 of the sequence variations in the RAS family. 20
were somatic (all in codons 12 or 13 of exon 2 of KRAS), while one in
HRAS was found in matched normal DNA (Supplemental Table
S4). The prevalence of KRAS mutations in our cohort of lung
adenocarcinomas was 12% (20/173). All confirmed somatic
mutations were found in adenocarcinomas except for a Gly12Asp
mutation in KRAS in a squamous cell carcinoma (Table 1).
67 of the 135 kinase domain sequence variations were
confirmed by analysis of sequence tracings from an independent
PCR isolate. 48 variants were also found in corresponding normal
samples (Supplemental Table S4). Two were of uncertain
significance, because we were unable to obtain a PCR product
from DNA from matched normal tissue (Supplemental Table
S4). Of the remaining 17 confirmed non-synonymous somatic
variants, 16 were found in genes known to be mutated in NSCLC,
i.e. EGFR, BRAF, and PIK3CA (Supplemental Table S4). The
prevalence of EGFR, BRAF, and PIK3CA mutations in lung
adenocarcinomas was 6 (13/234), ,1 (1/156), and 2% (2/132),
respectively. Clinical characteristics of all tumors containing
somatic mutations can be found in Table 1. One PIK3CA
mutation was found in a tumor that also contained a KRAS
mutation. No other tumor had more than one somatic mutation
(Table 2).
In one lung adenocarcinoma specimen from a current smoker,
we found a somatic heterozygous G to A mutation at nucleotide
position 2041 in exon 16 of FGFR4 (Figure 3). This mutation
would lead to substitution of lysine for glutamic acid at position
681 (Glu681Lys), 51 amino acids downstream of the highly
conserved DFG motif found in all protein kinases (Figure 4).
Using our ‘‘Mutagrator tool’’ (Figure 4; see methods),w e
determined that an analogous mutation has been reported in
a glioblastoma in ERBB2 (Glu914Lys) [11]. Moreover, the
glutamic acid at position 681 is highly conserved among various
kinases (Figure 4). The biological significance of the lung FGFR4
mutation remains to be determined experimentally. In total, this
mutation was found in 1 of 158 tumors. We did not identify any
other somatic mutations in this tumor (Table 2).
Figure 1. Genes sequenced in this study. The schematic diagram depicts the EGFR signaling pathway. Genes listed in red were sequenced only in
genomic DNAs from 217 tumors (‘‘Group 1’’). Genes listed in blue were sequenced only in WGA-treated DNA tumor samples (‘‘Group 2’’). Genes in
black were sequenced in both groups. Gene nomenclature is as reported in GenBank as of December 2006. See Supplemental Table S3 for clinical
characteristics of all tumors sequenced.
doi:10.1371/journal.pone.0000426.g001
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We report a comprehensive sequencing study of major genes in
a specific signaling pathway in a sizeable cohort of lung
adenocarcinoma tumor specimens. Previous large-scale mutational
profiling studies of lung cancer have examined either only the
exons encoding the activation loops of receptor tyrosine kinase
(RTK) genes (47 of 58 RTK genes) in 119 primary NSCLCs, of
which 70 (59%) were lung adenocarcinomas [4], or the coding
sequences of 518 protein kinases in a relatively limited number of
samples, i.e. 26 primary lung neoplasms (7 adenocarcinomas) and
seven cancer cell lines (6 adenocarcinomas) [32]. Here, we
examined a total of 261 tumor samples, predominantly adeno-
carcinomas, specifically for genetic alterations in genes encoding
major signaling proteins in the EGFR signaling pathway. We also
determined the status of a select set of other genes potentially
relevant to lung tumorigenesis.
Most of the somatic mutations we found have been reported,
including mutations in EGFR, KRAS, BRAF, and PIK3CA [3–5,11–
17]. The relative distribution of these mutations in our lung
adenocarcinomas matches that observed by others. The frequency
of EGFR and KRAS mutations was slightly lower than other
published series, possibly because the mutation detection software
that we used went through various stages of development during
this project [25]. We did not identify any somatic mutations in
HER2 or HER4. However, one of two variants of uncertain
significance (due to inability to PCR amplify a gene product from
matched normal DNA) was located in the kinase domain of HER2
(Arg784Cys) and has not been previously reported.
We did find a novel mutation (Glu681Lys) in the kinase domain
(exon16)ofFGFR4in1of158tumors.Thismutationisanalogousto
the previously reported Glu914Lys kinase domain mutation in
ERBB2 found in a glioblastoma [11]. Glu681 is highly conserved
region among various kinases, downstream of the DFG motif. Based
on the crystal structure of the related family member FGFR1
tyrosine kinase domain (PDB accession 1FGK) [33], the analogous
residue (Glu692) appears in close proximity to Ala626 in the TK
catalyticloop andArg661 intheTKactivation loop.SinceGlu692is
strongly positively charged and Arg661 is strongly negatively
charged, the close spatial proximity of these two residues would
likely lead to a strong ionic bond and therefore may be functionally
important. Extrapolating back to FGFR4, we propose that the
Glu681Lys mutation may alter the functional properties of the TK
catalytic domain by reversing the charge of residue 681, potentially
disrupting an ionic bond with residue Arg650, and thereby
disrupting normal function of FGFR4 (Figure 5).
FGFR4 is a monomeric receptor protein tyrosine kinase
possessing three immunoglobulin-like domains in the extracellular
region. The protein is one of four high-affinity receptors for
Figure 2. Schematic of overall results. A putative variation was defined as a sequence variation compared to a reference sequence in GenBank. After
visual inspection and exclusion of known SNPs and silent changes, there were 239 tumor sequences with a variation representing 174 distinct types
of variations. The sequence variations were further divided into three groups: 135 variations (99 distinct types) within exons encoding the kinase
domains of respective genes, 82 variations (69 types) in exons encoding areas outside the kinase domains of respective kinase genes, and 22
variations (6 types) in RAS family genes. Non-synonymous variations confirmed by sequence analysis of a 2
nd PCR were either somatic mutations or
variants found in matched normal tissue (listed in Supplemental Table S4). The significance of two novel variants, ERBB2 (exon 20, Arg784Cys) and
MAPK6 (exon 4, Val262Ile), is unclear, because we could not determine if the variants were also found in DNA from corresponding normal tissue.
doi:10.1371/journal.pone.0000426.g002
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angiogenic, mitogenic, and differentiation responses in cells [34].
Such ligands, when overexpressed in mouse lung epithelia,
stimulate alveolar type II cell hyperplasia and adenoma formation
[21–23]. Interestingly, Davies et al have reported that a lung
adenocarcinoma cell line also harbors a non-synonymous
mutation in exon 16 of FGFR4 – Pro672Thr [32]. [The Davies
et al paper referenced FGFR4 transcript variant 2; we referenced
variant 1, so the equivalent mutation would be Pro712Thr.]
Collectively, these data suggest a role for FGFR4 mutations in
a subset of lung adenocarcinomas. The Sanger group also found
two other somatic mutations in genes that encode the related
family members, FGFR1 and FGFR2, in lung cancer specimens.
The described FGFR1 and FGFR2 mutations occur outside the
kinase domain, but in identical positions to activating germline
mutations known to predispose to skeletal dysplasias. Other FGFR
gene alterations have also been reported in human cancers,
although rarely in exons encoding the kinase domain (reviewed in
[34]). We plan to characterize the functional consequences of the
two reported FGFR4 mutations and determine their prevalence in
independent lung and other tumor specimen banks.
This study has some potential limitations. First, we examined
only 39 genes. We did not sequence all related gene family
members such as RPS6KA1-6, MAP2K3, and MAP2K7. This study
also did not seek potential mutations in genes encoding adaptor
proteins or phosphatases that might affect the ERBB signaling
pathway. Second, WGA could have skewed the results by
selectively amplifying DNA from normal rather than tumor tissue.
However, evaluation of data from multiple assays has established
that base-calling discrepancies between amplified and unamplified
samples are minimal and not significantly different than that
observed after re-sequencing non-amplified samples [35,36].
Consistent with this, in all cases where we found an EGFR or
KRAS mutation in the original non-WGA-treated sample, we also
detected the same mutation in the corresponding WGA-treated
sample (n=14; data not shown). Finally, in this initial study, we
restricted our verification studies to non-synonymous variants in
the exons encoding kinase domains, in view of the clinical
significance of known somatic mutations in kinase domains. The
69 types of non-kinase domain sequence variations we identified
are currently undergoing confirmation. Nevertheless, the preva-
lence thus far of non-synonymous somatic mutations per megabase
of tumor sequenced in this study was 4.1 (37 total mutations/
9Mb). This rate is slightly higher than that found by others in
a mutational analysis of ,13,000 genes in 11 colorectal and 11
breast cancers [37].
Table 1. Clinical characteristics of patients whose tumors
contained a somatic mutation.
......................................................................
Tumor Mutation Age Gender Histology Smoking Stage
EGFR mutant
20t
1 exon 19 del 62 F AWBF Never IB
230t
1 exon 19 del 71 F ADENO Never IA
261t exon 19 del 68 M AWBF Former (.15 pk yr) IA
303t exon 19 del 76 M AWBF Former (.15 pk yr) IB
317t exon 19 del 77 F AWBF Former (#15 pk yr) IA
433t exon 19 del 81 F AWBF Never IB
428t exon 20 dup 61 M AWBF Former (#15 pk yr) IA
5t
1 Leu858Arg 53 F ADENO Former (#15 pk yr) IA
65t
1 Leu858Arg 85 M AWBF Former (#15 pk yr) IA
98t
1 Leu858Arg 64 F AWBF Former (#15 pk yr) IA
134t
1 Leu858Arg 68 M ADENO Former (#15 pk yr) IA
250t Leu858Arg 45 M AWBF Never IIIA
251t Leu858Arg 67 F AWBF Former (.15 pk yr) IA
KRAS mutant
12t Gly12Val 52 F ADENO Current IB
70t Gly12Val 58 M ADENO Current IIIA
86t Gly12Val 58 M ADENO Former (.15 pk yr) IIB
109t Gly12Val 78 F AWBF Never IB
110t Gly12Val 47 M ADENO Current IIB
404t Gly12Val 70 F ADENO Current IIIB
6t Gly12Cys 75 M AWBF Former (.15 pk yr) IA
29t Gly12Cys 78 F ADENO Former (.15 pk yr) IB
64t Gly12Cys 74 M ADENO Former (.15 pk yr) IIB
87t Gly12Cys 70 M AWBF Former (.15 pk yr) IA
290t Gly12Cys 75 F ADENO Former (.15 pk yr) IIIB
357t Gly12Cys 63 F ADENO Former (.15 pk yr) IIA
376t
2 Gly12Cys 67 F ADENO Former (.15 pk yr) IB
439t Gly12Cys 59 M AWBF Former (.15 pk yr) IA
1t Gly12Asp 75 F AWBF Former (.15 pk yr) IV
37t Gly12Asp 67 F AWBF Former (.15 pk yr) IB
L29t Gly12Asp 76 F SCC Never IIB
67t Gly12Asp 69 M AWBF Former (.15 pk yr) IA
68t Gly12Asp 80 M AWBF Former (.15 pk yr) IIIA
69t Gly13Cys 66 F AWBF Former (.15 pk yr) IA
PIK3CA mutant
376t
2 Glu545Lys 67 F AWBF Former (.15 pk yr) IB
421t Glu545Lys 80 F ADENO Former (.15 pk yr) IA
BRAF mutant
408t Val600Glu 64 M AWBF Former (.15 pk yr) IB
FGFR4 mutant
410t Glu681Lys 66 F ADENO Current IIIB
Smoking history is defined as never smokers (,100 lifetime cigarettes), former
smokers (quit $1 year prior to diagnosis), or current (quit ,1 year prior to
diagnosis. Former smokers were further defined as having smoked #15 pack
years (number of packs of cigarettes smoked per day multiplied by the number
of years the person has smoked) or .15 pack years.
1Mutation previously reported (5).
2Tumor contained both a KRAS and PIK3CA mutation. Abbreviations: ADENO,
adenocarcinoma; AWBF, adenocarcinoma with bronchioalveolar features (38);
SCC, squamous cell carcinoma; dup, duplication; del, deletion. AWBF is
equivalent to the WHO classification: adenocarcinoma, mixed subtype, with
BAC component (39).
doi:10.1371/journal.pone.0000426.t001
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Table 2. Mutations observed in EGFR, KRAS, BRAF, and FGFR4
in lung adenocarcinomas.
......................................................................
# Samples EGFR KRAS BRAF FGFR4
13
1 Xw t w t w t
20
2 wt X wt wt
1w t w t X w t
1w t w t w t X
Except for one KRAS mutant tumor which also contained a PIK3CA mutation, no
other tumor with a mutation in one of these genes had a mutation in the other
3 genes. X denotes a mutation.
15 EGFR mutations were previously reported (5).
2One KRAS mutation was found in a squamous cell carcinoma. Abbreviations:
wt, wild-type.
doi:10.1371/journal.pone.0000426.t002
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PLoS ONE | www.plosone.org 5 May 2007 | Issue 5 | e426Figure 3. Analysis of FGFR4. Forward/reverse sequencing chromatograms for the mutation identified in exon 16 of FGFR4 in tumor and matched
normal samples. The nucleotide change is c.2041G.A, that would lead to substitution of lysine for glutamic acid at position 681.
doi:10.1371/journal.pone.0000426.g003
Figure 4. Amino acid alignment of the FGFR4 kinase domain with other tyrosine kinase domains found to be altered in human cancers. The DFG
motif found in all kinases is underlined. The glutamic acid residue at position 681 in FGFR4 (boxed) is highly conserved amongst the various kinases.
Amino acids affected by mutations and reported in the COSMIC (Catalogue of Somatic Mutations in Cancer) database appear in yellow. The
analogous Glu914 residue in ERBB2 (boxed) has been found to be mutated in a glioblastoma. Figure adapted from a screenshot of the ‘‘Mutagrator’’
bioinformatics tool developed for this study. The previously reported Pro712Thr mutation in FGFR4 was also identified by the Mutagrator tool but is
not shown. See methods for more details.
doi:10.1371/journal.pone.0000426.g004
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PLoS ONE | www.plosone.org 6 May 2007 | Issue 5 | e426This study represents an early step towards an understanding of
the lung cancer oncogenome. Our results suggest that the majority
of gain-of-function mutations within kinase genes in the EGFR
signaling pathway may have been identified. We await results from
the NCI/NHGRI-sponsored ‘‘technical demonstration project’’ –
a pilot project for The Cancer Genome Atlas initiative, in which
approximately 200 highly-curated lung adenocarcinomas are
being analyzed for chromosomal gains and losses simultaneously
with mutational profiling of about 1000 genes thought to be
relevant to lung tumorigenesis. Efforts such as these should
contribute towards the identification of the full spectrum of
somatic mutations found in lung adenocarcinomas.
SUPPORTING INFORMATION
Table S1 Gene, GenBank accession number, and exonic
coverage of genes sequenced in this study.
Found at: doi:10.1371/journal.pone.0000426.s001 (0.06 MB
DOC)
Table S2 List of primers used to verify putative variants.
Found at: doi:10.1371/journal.pone.0000426.s002 (0.15 MB
DOC)
Table S3 Clinical characteristics of patients whose tumors were
analyzed. Group 1 was used for sequencing the ‘‘core’’ genes.
Group 2 was used for sequencing the ‘‘exploratory’’ genes. Some
tumors and genes overlapped between the two groups. Smoking
history is defined as never smokers (,100 lifetime cigarettes),
former smokers (quit $1 year prior to diagnosis), or current (quit
,1 year prior to diagnosis). See text and Figure 1 for more detail.
1Adeno includes adenocarcinoma with bronchioalveolar features
(n=79, n=27 for Group 1 and 2, respectively). Abbreviations:
Adeno, adenocarcinoma; SCC, squamous cell carcinoma.
Found at: doi:10.1371/journal.pone.0000426.s003 (0.04 MB
DOC)
Table S4 List of variants verified. Group headings correspond to
groups in bottom row of Figure 2. Variants found in normal tissue
did not have an existing entry in dbSNP. 1A total of 5 EGFR
mutations (exon 19 del, n=1: exon 21 L858R, n=4) have been
previously reported (5). 2Variants with high frequency were not
verified in all samples. If a variant was also found in DNA from
five matched normals, no further samples were verified. Abbrevia-
tions: del, deletion; dup, duplication.
Found at: doi:10.1371/journal.pone.0000426.s004 (0.08 MB
DOC)
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